Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
出版年份 2021 全文链接
标题
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
作者
关键词
-
出版物
Blood Advances
Volume 5, Issue 9, Pages 2294-2304
出版商
American Society of Hematology
发表日期
2021-04-30
DOI
10.1182/bloodadvances.2021004367
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation
- (2020) Alexandros Spyridonidis BLOOD
- Molecular MRD status and outcome after transplantation in NPM1-mutated AML
- (2020) Richard Dillon et al. BLOOD
- Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?
- (2020) Adriano Venditti et al. LEUKEMIA
- Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
- (2020) Robert P. Hasserjian et al. BLOOD
- Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia
- (2020) Ing S. Tiong et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Heuser et al. ANNALS OF ONCOLOGY
- Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial
- (2020) Silke Kapp-Schwoerer et al. BLOOD
- NGS‐Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse
- (2019) Richard D. Press et al. AMERICAN JOURNAL OF HEMATOLOGY
- Can we incorporate MRD assessment into clinical practice in AML?
- (2019) Gert Ossenkoppele et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- MRD in AML: The Role of New Techniques
- (2019) Maria Teresa Voso et al. Frontiers in Oncology
- GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
- (2019) Adriano Venditti et al. BLOOD
- Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group
- (2019) Frank G. Rücker et al. BLOOD
- Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia
- (2019) Federico Lussana et al. Cancers
- Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
- (2019) Megan Othus et al. BONE MARROW TRANSPLANTATION
- The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience
- (2019) Justin Loke et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
- (2019) Christopher S. Hourigan et al. JOURNAL OF CLINICAL ONCOLOGY
- MRD evaluation of AML in clinical practice: are we there yet?
- (2019) Sylvie D. Freeman et al. Hematology-American Society of Hematology Education Program
- Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu
- (2018) Maria H Gilleece et al. AMERICAN JOURNAL OF HEMATOLOGY
- Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
- (2018) Mithun Vinod Shah et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
- (2018) Kiyomi Morita et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
- (2018) Felicitas Thol et al. BLOOD
- Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2018) Catherine J. Lee et al. BONE MARROW TRANSPLANTATION
- Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
- (2018) Uwe Platzbecker et al. LANCET ONCOLOGY
- Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
- (2018) Nikhil Patkar et al. Oncotarget
- Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
- (2017) Pierre Hirsch et al. HAEMATOLOGICA
- Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
- (2017) Sarah A. Buckley et al. HAEMATOLOGICA
- Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
- (2017) Pierre Hirsch et al. HAEMATOLOGICA
- Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
- (2017) Sarah A. Buckley et al. HAEMATOLOGICA
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
- (2016) Y Zhou et al. LEUKEMIA
- MRD in AML: does it already guide therapy decision-making?
- (2016) G. Ossenkoppele et al. Hematology-American Society of Hematology Education Program
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
- (2015) Paresh Vyas et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation
- (2015) Chiara Brambati et al. HAEMATOLOGICA
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
- (2015) Jeffery M. Klco et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation
- (2015) Chiara Brambati et al. HAEMATOLOGICA
- Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
- (2014) Akiyoshi Takami et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Next Generation MRD
- (2014) Christopher S. Hourigan BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
- (2014) R B Walter et al. LEUKEMIA
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
- (2013) R. B. Walter et al. BLOOD
- Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
- (2011) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started